Study guide
3.6 Neurocognitive Disorders
ANCC Psychiatric-Mental Health Nurse Practitioner PMHNP-BC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Scientific Foundation
1.1 Neuroanatomy and Brain Function 1.2 Neurotransmitters and Synaptic Transmission 1.3 Neurodevelopmental and Neuroendocrine Mechanisms 1.4 Psychbehavioral Genetics and Epigenetics 1.5 Psychoneuroimmunology and Inflammatory Pathways 1.6 Psychopathology and Diagnostic Foundations 1.7 Evidence-Based Practice and Research Methodologies 1.8 Lifespan Growth and Development Theories 1.9 Health Promotion and Disease Prevention
2 Chapter 2: Advanced Practice Skills
2.1 Comprehensive Psychiatric Interview and Health History 2.2 Mental Status Examination (MSE) Concepts and Clinical Application 2.3 Physical and Neurological Assessment in Psychiatry 2.4 Diagnostic Laboratory and Imaging Interpretation 2.5 Suicide Risk Assessment and Safety Formulation 2.6 Violence and Homicide Risk Assessment 2.7 Substance Use, Intoxication, and Withdrawal Assessment 2.8 Cultural Competence and Social Determinants of Mental Health 2.9 Therapeutic Alliance and Clinical Communication 2.10 Functional and Diagnostic Risk Stratification
3 Chapter 3: Diagnosis and Treatment
3.1 Neurodevelopmental and Schizophrenia Spectrum Disorders 3.2 Bipolar and Related Disorders 3.3 Depressive Disorders 3.4 Anxiety Disorders, OCD, and Trauma-Related Disorders 3.5 Substance-Related and Addictive Disorders 3.6 Neurocognitive Disorders 3.7 Personality Disorders 3.8 Feeding/Eating, Sleep-Wake, and Somatic Symptom Disorders 3.9 Psychopharmacology Foundations: Antipsychotics and Mood Stabilizers 3.10 Psychopharmacology Foundations: Antidepressants, Anxiolytics, and Stimulants
4 Chapter 4: Psychotherapy and Related Theories
4.1 Cognitive Behavioral Therapy (CBT) and Dialectical Behavior Therapy (DBT) 4.2 Psychodynamic and Psychoanalytic Theories 4.3 Humanistic, Person-Centered, and Motivational Interviewing 4.4 Family and Group Psychotherapy Modalities 4.5 Integrative and Complementary Mental Health Approaches
5 Chapter 5: Ethics, Legal Principles, and Cultural Care
5.1 Patient Autonomy, Informed Consent, and Capacity 5.2 Involuntary Commitment and Patient Rights 5.3 Confidentiality, HIPAA, and Duty to Protect 5.4 Professional Scope of Practice and Prescriptive Authority 5.5 Malpractice, Liability, and Risk Management 5.6 Health Policy, Advocacy, and Mental Health Parity 5.7 Quality Improvement, Patient Safety, and Interprofessional Collaboration 5.8 Telepsychiatry, Technology, and Ethical Care Delivery
3.6 Neurocognitive Disorders
Key Takeaways Explain This Topic AI
Delirium is a medical emergency characterized by acute onset (hours to days), fluctuating attention/awareness, and cognitive disturbances, diagnosed via CAM (Confusion Assessment Method; requires Features 1 + 2 + [3 or 4]).
DSM-5-TR categorizes neurocognitive disorders across 6 core cognitive domains: Complex Attention, Executive Function, Learning & Memory, Language, Perceptual-Motor, and Social Cognition.
Alzheimer's Disease features extracellular beta-amyloid 42 plaques and intracellular hyperphosphorylated tau tangles, presenting with insidious short-term memory decline (MoCA < 26; MMSE score decline of 2-4 points/year).
Vascular Neurocognitive Disorder manifests as a step-wise cognitive decline linked to cerebrovascular events, confirmed by neuroimaging showing lacunar infarcts or severe leukoaraiosis.
Dementia with Lewy Bodies (DLB) requires core features of fluctuating cognition, recurrent detailed visual hallucinations (> 80% of patients), spontaneous parkinsonism, and REM sleep behavior disorder; typical antipsychotics cause severe neuroleptic sensitivity in up to 50% of patients.
Last updated: July 2026
Core Neurocognitive Domains (DSM-5-TR)
Neurocognitive disorders (NCDs) represent a decline from a previously attained level of cognitive functioning. Diagnosis requires systematic evaluation across six core cognitive domains defined by the DSM-5-TR:
Complex Attention: Sustained attention, divided attention, selective attention, and processing speed.
Executive Function: Planning, decision-making, working memory, responding to feedback, flexibility, and overriding habits (inhibition).
Learning and Memory: Immediate memory, recent memory (free recall, cued recall, recognition memory), and long-term/very long-term memory (semantic, autobiographical, implicit learning).
Language: Expressive language (naming, word finding, fluency, grammar) and receptive language (comprehension).
Perceptual-Motor: Visual perception, visuoconstructive reasoning, perceptual-motor coordination, and praxis (executing motor acts).
Social Cognition: Recognition of emotions, theory of mind (empathy, understanding others' mental states), and behavioral self-regulation.
Diagnostic Severity Thresholds
Mild Neurocognitive Disorder: Substantial cognitive decline in one or more domains, but cognitive deficits do not interfere with capacity for independence in everyday activities (e.g., complex instrumental activities of daily living [IADLs] like managing finances or medications are preserved, though requiring greater effort or compensatory strategies).
Major Neurocognitive Disorder (Dementia): Significant cognitive decline in one or more domains that interferes with independence in everyday activities (requiring assistance with IADLs or basic activities of daily living [ADLs]).
Delirium: Clinical Syndrome & PMHNP Management
Delirium is a life-threatening medical emergency characterized by an acute disturbance in attention and awareness that fluctuates in severity over hours to days. It is a neuropsychiatric manifestation of underlying systemic physiological dysfunction.
DSM-5-TR Diagnostic Criteria
Criterion A: A disturbance in attention (reduced ability to direct, focus, sustain, and shift attention) and awareness (reduced orientation to the environment).
Criterion B: The disturbance develops over a short period of time (usually hours to a few days), represents a change from baseline attention and awareness, and tends to fluctuate in severity during the course of a day.
Criterion C: An additional disturbance in cognition (e.g., memory deficit, disorientation, language, visuospatial ability, or perception).
Criterion D: The disturbances are not better explained by another preexisting, established, or evolving neurocognitive disorder and do not occur in the context of a severely reduced level of arousal, such as coma.
Criterion E: Evidence from the history, physical examination, or laboratory findings that the disturbance is a direct physiological consequence of another medical condition, substance intoxication or withdrawal, or exposure to a toxin, or is due to multiple etiologies.
Clinical Subtypes
Hyperactive: Characterized by psychomotor agitation, restlessness, hypervigilance, hallucinations, and emotional lability. Often recognized quickly.
Hypoactive: Characterized by lethargy, sluggishness, psychomotor slowing, and apathy. Frequently misdiagnosed as depression or severe dementia, carrying a higher mortality rate due to delayed intervention.
Mixed: Fluctuates rapidly between hyperactive and hypoactive states.
Etiology: The DELIRIUM Mnemonic
- Letter Etiology / Examples
- D Drugs: Anticholinergics, sedatives/hypnotics, opioids, corticosteroids, polypharmacy
- E Electrolyte Imbalance: Hyponatremia, hypercalcemia, hypoglycemia, severe dehydration
- L Lack of drugs: Withdrawal from alcohol, benzodiazepines, or barbiturates
- I Infection: Urinary tract infection (UTI), pneumonia, sepsis, meningitis, encephalitis
- R Reduced sensory input: Blindness, deafness, sensory deprivation or overload in ICU
- I Intracranial: Stroke, subdural hematoma, seizure/postictal state, elevated ICP
- U Urinary/Fecal retention: Severe constipation, urinary outlet obstruction
- M Myocardial/Metabolic: Heart failure, MI, hypoxia, hypercapnia, hepatic encephalopathy, uremia
- Diagnostic Evaluation Workup
Laboratory Panel: CBC, Comprehensive Metabolic Panel (CMP: electrolytes, BUN, creatinine, LFTs, calcium), Urinalysis and urine culture, Thyroid-stimulating hormone (TSH), Serum Vitamin B12 and Folate, Rapid Plasma Reagin (RPR) or VDRL, Blood alcohol and urine drug screen.
Physiological & Cardiac: Arterial Blood Gas (ABG), Electrocardiogram (ECG), Chest X-ray.
Neuroimaging & Specialized Tests: Non-contrast Brain CT or MRI (if focal neurological signs or head trauma), Lumbar Puncture (if meningitis/encephalitis suspected), Electroencephalogram (EEG) showing generalized diffuse background slowing (delirium) vs. focal spikes or normal alpha rhythm (pseudodementia/depression).
PMHNP Management & Intervention Protocols
Primary Goal: Identify and treat the underlying medical cause immediately.
Non-Pharmacological Measures (First-Line): Environmental reorientation (clocks, calendars, family presence), maintaining sleep-wake cycles (daylight exposure, quiet night environment), sensory aids (ensuring glasses and hearing aids are worn), early mobilization, hydration. Avoid physical restraints , which increase agitation and fall risk.
Pharmacological Interventions (Reserved strictly for severe agitation/psychosis endangering patient or staff safety):
Haloperidol (Haldol): High-potency FGA, 0.5 mg to 2.0 mg PO/IM. Minimal anticholinergic effect. Monitor QTc interval on EKG.
Second-Generation Antipsychotics: Quetiapine (12.5–25 mg), Olanzapine (2.5–5 mg), or Risperidone (0.25–0.5 mg).
Contraindications: Avoid Benzodiazepines in delirium UNLESS the delirium is caused by alcohol or sedative-hypnotic withdrawal (Delirium Tremens), as benzodiazepines worsen delirium from other etiologies.
Differential Diagnosis: Major Neurocognitive Disorders
Neurocognitive Disorder Onset & Progression Core Clinical Features Histopathology / Biomarkers Focal Neurological Signs First-Line Pharmacotherapy
Alzheimer's Disease (AD) Insidious onset; gradual, continuous progression Early anterograde memory impairment; late apraxia, agnosia, executive dysfunction Extracellular Beta-Amyloid plaques; Intracellular hyperphosphorylated Tau tangles; Acetylcholine deficit Absent early; present in terminal stages Cholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine) + Memantine
Vascular NCD Abrupt onset or step-wise decline Executive dysfunction early; cognitive drops correlated with cerebrovascular events Ischemic infarcts, lacunar strokes, subcortical leukoaraiosis on MRI Present early (hemiparesis, hyperreflexia, gait ataxia, pseudobulbar palsy) Cardiovascular risk control, antiplatelet therapy, Cholinesterase Inhibitors
Dementia with Lewy Bodies (DLB) Insidious onset; fluctuating course Triad: Fluctuating alertness, detailed visual hallucinations, spontaneous parkinsonism; REM sleep behavior disorder Alpha-synuclein neuronal inclusions (Lewy bodies) in cortex and brainstem Present early (parkinsonian tremor, rigidity, bradykinesia) Cholinesterase Inhibitors; Low-dose Quetiapine/Pimavanserin for psychosis
Frontotemporal NCD (FTD) Gradual onset; younger age (45–65 yrs) Behavioral variant (disinhibition, apathy, hyperorality) OR Primary Progressive Aphasia Frontotemporal lobar degeneration; Tau or TDP-43 protein aggregates Absent early; primitive reflexes (palmar grasp) late SSRIs (Sertraline, Trazodone) for behavior; Cholinesterase Inhibitors contraindicated
Normal Pressure Hydrocephalus Subacute to chronic progression Classic Triad: "Wet, Wobbly, Wacky" (Urinary incontinence, Magnetic gait, Dementia) Ventriculomegaly out of proportion to sulcal atrophy on MRI/CT Prominent early magnetic, broad-based gait ataxia Therapeutic Lumbar Puncture; Ventriculoperitoneal (VP) Shunting
Creutzfeldt-Jakob Disease (CJD) Rapidly progressive (< 1 year duration) Rapid dementia, prominent myoclonus, ataxia, extrapyramidal/pyramidal signs Spongiform encephalopathy; Prion protein (PrP^Sc); CSF 14-3-3 protein Present early (myoclonus, cerebellar ataxia, startle response) Symptomatic/Palliative care only
- Subtype Profiles & PMHNP Prescribing Guidelines
- 1. Alzheimer's Disease (AD)
Pathophysiology: Widespread loss of cholinergic neurons originating in the Nucleus Basalis of Meynert . Beta-amyloid plaques accumulate extracellularly, causing neuroinflammation, while intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein disrupt axonal transport.
Genetics: Early-onset AD (<65 years, autosomal dominant): Mutations in APP (Chromosome 21), PSEN1 (Chromosome 14), and PSEN2 (Chromosome 1). Late-onset AD: Apolipoprotein E epsilon 4 ( APOE-ε4 ) allele on Chromosome 19 increases risk.
Pharmacological Management:
Cholinesterase Inhibitors (Mild to Severe AD): Donepezil (Aricept) (5–10 mg QD; up to 23 mg), Rivastigmine (Exelon) (oral or transdermal patch—ideal for dysphagia or GI intolerance), Galantamine (Razadyne) . Common side effects: Nausea, vomiting, diarrhea, bradycardia, syncope, insomnia, vivid dreams.
NMDA Receptor Antagonist (Moderate to Severe AD): Memantine (Namenda) (5–20 mg QD). Blocks pathological tonic influx of glutamate into NMDA receptors, preventing excitotoxic neurotoxicity. Can be combined with Donepezil (Namzaric).
Disease-Modifying Biologics: Monoclonal antibodies targeting amyloid-beta (e.g., Lecanemab, Donanemab). Requires baseline MRI and monitoring for ARIA (Amyloid-Related Imaging Abnormalities) : ARIA-E (edema/effusion) and ARIA-H (microhemorrhage/siderosis).
2. Vascular Neurocognitive Disorder
Pathophysiology: Result of multi-infarct dementia, single strategic stroke, or subcortical ischemic vascular disease (small vessel disease affecting thalamocortical circuits).
Clinical Presentation: Executive dysfunction (impaired planning, sequencing, processing speed) typically exceeds memory impairment in early stages. Step-wise decline is classic.
PMHNP Management: Focus on secondary prevention of cerebrovascular events: antihypertensives, statins, diabetes management, smoking cessation, antiplatelet agents (Aspirin, Clopidogrel). Cholinesterase inhibitors are beneficial if mixed AD/Vascular etiology exists.
3. Dementia with Lewy Bodies (DLB) vs. Parkinson's Disease Dementia (PDD)
The 1-Year Rule:
DLB: Cognitive decline and neurobehavioral symptoms occur before or simultaneously with (within 1 year of) parkinsonian motor signs.
PDD: Extrapyramidal motor signs (Parkinson's disease) are established for more than 1 year before the onset of neurocognitive decline.
CRITICAL PMHNP WARNING — Antipsychotic Hypersensitivity: Up to 50% of DLB patients exhibit life-threatening reactions to antipsychotics (severe EPS, acute deterioration of rigidity, irreversible parkinsonism, somnolence, and precipitous NMS). First-line treatment for psychotic symptoms is Cholinesterase Inhibitors. If severe, distressing hallucinations persist, low-dose Quetiapine (12.5–50 mg), Clozapine , or Pimavanserin (Nuplazid) (selective 5-HT2A inverse agonist) should be used.
4. Frontotemporal Neurocognitive Disorder (FTD)
Behavioral Variant (bvFTD): Early disinhibition (socially inappropriate behavior, loss of decorum), apathy, loss of sympathy/empathy, hyperorality (dietary changes, craving sweets, putting inedible objects in mouth), repetitive/compulsive behaviors.
Language Variants (Primary Progressive Aphasia): Semantic variant (loss of word meaning/object identification) vs. Nonfluent/agrammatic variant (hesitant, effortful speech with grammatical errors).
Prescribing Pearl: Cholinesterase inhibitors are ineffective and frequently exacerbate behavioral agitation, disinhibition, and GI upset . SSRIs (Sertraline, Trazodone) are preferred for disinhibition, compulsive behaviors, and mood symptoms.
5. Other Specific Etiologies
Normal Pressure Hydrocephalus (NPH): Ventricular enlargement with normal CSF opening pressure. Symptom triad: Gait Disturbance (broad-based, slow, short-stepped, "magnetic" gait—feet glued to floor; usually the first symptom), Urinary Incontinence (urgency and frequency), and Dementia (psychomotor slowing, apathy). Treatment: Ventriculoperitoneal (VP) shunt placement.
Creutzfeldt-Jakob Disease (CJD): Transmissible spongiform encephalopathy caused by prions. Presentation: Rapidly progressive dementia, startle-induced myoclonus , cerebellar ataxia. Diagnostic findings: Generalized periodic sharp wave complexes on EEG; elevated 14-3-3 protein or tau protein in CSF; hyperintensity in basal ganglia/cortex ("cortical ribboning") on diffusion-weighted MRI.
HIV-Associated Neurocognitive Disorder (HAND): Subcortical pattern of impairment featuring psychomotor slowing, executive dysfunction, apathy, and motor clumsiness. Treatment: Optimization of combination Antiretroviral Therapy (cART) with high Central Nervous System Penetration Effectiveness (CPE) scores.
Loading diagram...